SEC Form 8-K Summary
Registrant: GX Acquisition Corp. (NYSE? Actually Nasdaq-listed GXGX, GXGXU and GXGXW) Filing date: January 8, 2021. The filing concerns a proposed business combination with Celularity Inc.; it is not a report of Celularity’s operating results for a fiscal reporting period.
Business Context and Transaction
GX Acquisition Corp., a blank-check company, entered into a Merger Agreement with Celularity Inc., Alpha First Merger Sub, Inc. and Alpha Second Merger Sub, LLC. The transaction is structured as a two-step merger intended to result in Celularity becoming a wholly owned business of the combined entity.
- Celularity stockholders are expected to receive up to 147,327,224 newly issued shares of GX Class A common stock.
- The stated reference value is approximately $10.15 per share, subject to the agreement’s exchange-ratio calculations.
- Celularity’s preferred stock will convert into Celularity common stock before the merger.
- Outstanding Celularity warrants and options are generally expected to convert into warrants and options for GX Class A common stock, subject to adjustment mechanics.
Financing and Key Financial Information
| Item | Reported information |
|---|---|
| PIPE financing | 8,340,000 GX Class A shares at $10.00 per share |
| Aggregate PIPE proceeds | $83.4 million |
| Merger consideration | Up to 147,327,224 GX Class A shares |
| Revenue, profit and margins | The filing does not provide clear current-period or comparable-period operating results. |
| Cash flow and liquidity | The filing does not provide clear cash-flow or liquidity figures. Closing requires GX to have at least $5,000,001 of net tangible assets. |
| Debt | The filing does not provide a clear debt balance or debt-maturity schedule. |
Material Changes, Outlook and Risks
- The proposed transaction was newly announced on January 8, 2021; no completed merger or closing was reported in this filing.
- Closing is subject to stockholder approvals, HSR Act clearance, effectiveness of the registration statement, Nasdaq listing approval, required transaction agreements and the absence of a material adverse effect.
- The parties expected the closing by May 20, 2021, subject to permitted extensions tied to GX’s business-combination deadline, potentially up to June 30, 2021.
- Celularity stockholders holding approximately 82% of its capital stock signed support agreements to vote for the transaction, subject to stated conditions.
- GX’s sponsor, officers and directors agreed to support the transaction and waive certain anti-dilution adjustment rights.
- Certain Celularity stockholders will be subject to lock-ups generally ending on the earlier of one year after closing or specified stock-price or liquidation events.
- The PIPE shares are to be issued in an unregistered private placement under Section 4(a)(2), with resale-registration obligations after closing.
- Risks include failure to complete the merger or PIPE financing, clinical and regulatory risks, manufacturing scale-up, intellectual-property matters, future funding needs, competition, COVID-19 impacts, litigation and the possibility that projected benefits or business performance do not materialize.
Important Facts for Investors to Verify
- Whether the merger received all required GX and Celularity stockholder, regulatory and listing approvals.
- The final exchange ratio, share issuance, dilution and treatment of Celularity options and warrants.
- Whether the $83.4 million PIPE financing closed and whether any subscription agreements terminated.
- GX’s trust-account balance, redemptions, remaining net tangible assets and post-transaction liquidity.
- Celularity’s audited financial statements, revenue, losses, cash burn, debt and projected capital requirements, which are not presented clearly in this 8-K.
- The effectiveness of the Form S-4/proxy statement and the definitive terms of the completed transaction.